Randomized Study of Sorafenib Dose Escalation in Patients With Previously Untreated Metastatic Renal Cell Carcinoma
Public ClinicalTrials.gov record NCT00557830. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Randomized Phase IIb Study of Sorafenib Dose Escalation in Patients With Previously Untreated Metastatic Renal Cell Carcinoma (RCC)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The primary objective of this study is to compare the effectiveness of a dose-escalation regimen (400 to 800mg bid) relative to the standard dosing regimen (400mg bid) of sorafenib given in patients with metastatic RCC. The secondary objectives are to evaluate the effects of the dose-escalation regimen on the quality of life (QoL) of patients with metastatic RCC and to characterize the safety and tolerability profile of a dose-escalation regimen of sorafenib in patients with metastatic RCC.
Study identification
- NCT ID
- NCT00557830
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 12 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 2008 (Type not available)
- Primary completion
- Apr 2011 (Actual)
- Completion
- Apr 2011 (Actual)
- Last update posted
- Jul 18, 2013
2008 – 2011
United States locations
- U.S. sites
- 13
- U.S. states
- 10
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Clopton Clinic | Jonesboro | Arkansas | 72401 | — |
| Wilshire Oncology Medical Group, Inc. | La Verne | California | 91750 | — |
| Advanced Medical Specialties | Miami | Florida | 33176 | — |
| Northeast Georgia Cancer Care | Athens | Georgia | 30607 | — |
| Peachtree Hematology Oncology Consultants | Atlanta | Georgia | 30309 | — |
| Central Georgia Cancer Care | Macon | Georgia | 31201 | — |
| Northwest Georgia Oncology Centers | Marietta | Georgia | 30060 | — |
| Mid-Illinois Hematology and Oncology Associates, Ltd. | Normal | Illinois | 61761 | — |
| Hematology Oncology Centers of the Northern Rockies | Billings | Montana | 59101 | — |
| Gaston Hematology and Oncology | Gastonia | North Carolina | 28054 | — |
| Pacific Oncology, PC | Beaverton | Oregon | 97006 | — |
| The Lancaster Cancer Center, Ltd | Lancaster | Pennsylvania | 17605 | — |
| The West Clinic | Memphis | Tennessee | 38120 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00557830, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 18, 2013 · Synced Oct 1, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00557830 live on ClinicalTrials.gov.